News and Announcements
Dealt Limited (ASX: DET) developed Australia’s first real time Commercial Real Estate finance marketplace to assist borrowers to secure non-bank finance
- Published April 08, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
“The dealt.com.au platform was created to provide a platform for developers and investors to access capital for their next project.
We now have over 70 non-bank lenders and family offices looking to fund right across the real estate capital stack.”
James Storey, Founder of Dealt Limited (ASX: DET)
Executive Summary
Dealt Ltd (ASX: DET) is an IPO stage business listing on the ASX in May 2021. Dealt has developed Australia’s first real time Commercial Real Estate finance marketplaces to assist borrowers to secure non-bank finance.
Dealt Group is a diversified business that will specialise in Commercial Real Estate (CRE).
Dealt has been established in response to the emergence of private, non-bank lenders in the $302 billion Australian and New Zealand Commercial Real Estate (CRE) lending market to provide alternative lending sources for borrowers.
Investment Highlights
- Technology-Enabled Real Estate LendingOnline lending platform with scalability including potential future overseas distribution agreements
- Diverse Portfolio of RE LoansDiversified exposure to a portfolio of well-secured, Commercial Real Estate (CRE) senior loans throughout metropolitan Australia and New Zealand
- Diversified Funding SourcesMultiple capital options including warehouse facilities and private debt capital
- Sponsor and Founders Co-Investment360 Capital Group and founders have committed up to 19.0% as co-investment capital
- 15 -Year Real Estate Track Record360 Capital has never lost capital across its real estate lending activities. 360 Capital has transacted over $3 billion across the capital stack.
Investment Offering
Dealt Ltd is looking to undertake a restructure and recapitalisation offer on ASX to raise A$28.4 million via the issue of 56.8 million shares at an offer price of A$0.50 per share.
Click here to register for the Dealt webinar to learn more about the opportunity.
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
